Filing Flows › Editas Medicine (EDIT) › Stock forecast & fair value
Editas Medicine (EDIT) stock forecast and price target
Editas Medicine (EDIT) trades at $2.57. 10 analysts' median price target is $5.50 (+114%), from $1.00 to $15.00.
Editas Medicine's latest quarter
Editas Medicine, Q2 2026: revenue $11.9M (+232% year over year), operating margin -156.0%, net loss $18.2M, operating cash flow −$29.6M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for EDIT stock?
The median of 10 analysts' 12-month targets is $5.50, +114% from $2.57; the range is $1.00 to $15.00. The average rating is none.
Does Editas Medicine usually beat earnings estimates?
It beat the consensus EPS estimate in 75% of the quarters on record.
Is EDIT stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.